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Abstract 
Background: We aimed to identify healthcare needs, expectations, utilization, and the experienced treatment effects 
in a population of Dutch patients with hereditary spastic paraplegia (HSP).
Methods: We distributed an online questionnaire among 194 adult persons with HSP in the Netherlands, of which 
166 returned a fully completed version. After applying predefined exclusion criteria, 109 questionnaires from persons 
with pure HSP were analysed.
Results: Healthcare needs and expectations were primarily focused on the relief of muscle stiffness and reduction of 
balance and gait impairments (65–80%), but many participants also expressed needs regarding relief of non-motor 
symptoms (e.g. pain, fatigue), emotional problems, impaired sleep and self-care capacity, and participation problems 
(> 60%). Remarkably, despite these frequent needs, relatively few participants (< 33%) expected to be able to improve 
in these additional domains. Rehabilitation physicians and physiotherapists were more frequently consulted than 
neurologists and occupational therapists, respectively. Physiotherapy was the most often proposed non-pharmaco-
logical intervention (85%), followed by orthopedic footwear (55%) and splints (28%). Approximately one third of the 
participants was never offered any pharmacological (spasmolytic) treatment. Spasmolytic oral drugs, injections, and 
intrathecal baclofen were given to 41%, 26%, and 5% of the participants, respectively. Independent of the type of 
pharmacological intervention, 35–46% of these participants experienced decreased spastiticy and improved general 
fitness. Other experienced effects differed per type of intervention.
Conclusions: Based on this web-based survey in the Netherlands, there seems to be ample room for improvement 
to meet and attune the healthcare needs and expectations of people with HSP concerning both their motor and non-
motor symptoms and functional limitations. In addition, the provision of adequate information about non-pharmaco-
logical and pharmacological interventions seems to be insufficient for many patients to allow shared decision making. 
These conclusions warrant a more pro-active attitude of healthcare providers as well as an interdisciplinary approach 
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Background
Hereditary spastic paraplegia (HSP) is a group of inher-
ited neurological disorders characterized by progressive 
bilateral lower limb spasticity and muscle weakness [1]. 
Many complex forms of HSP exist, but in patients with 
‘pure HSP’ the main neurological feature is a slowly pro-
gressive spastic paraparesis [2–4]. In a previous publi-
cation [5], we reported the first results of a web-based 
survey in the Netherlands, focusing on the spasticity-
related complaints and activity limitations as experienced 
by patients with HSP. These data showed that patients 
with pure HSP experienced the greatest burden from 
muscle stiffness, physical and mental fatigue, leg and back 
pain, and limitations with regard to standing and walking 
activities. Furthermore, they reported a high frequency 
of walking aid use, fall incidents, and fear of falling. These 
findings are in line with the results of a previously pub-
lished, qualitative study amongst persons with pure HSP 
[6]. Additionally, the participants in this qualitative study 
reported that they often missed the support from health-
care professionals in dealing with their spasticity-related 
complaints and activity limitations. More specifically, 
they expressed a need for personalized guidance and 
advice on how to adjust to the consequences of HSP in 
everyday life [6]. In their Cochrane review on multidis-
ciplinary treatment following focal spasmolysis in people 
post stroke, Demetrios et al. stated that “using appropri-
ate patient-centered outcomes of rehabilitations inter-
ventions with standardized measures may provide a more 
holistic picture” [7]. This was the reason to also include 
specific questions about healthcare needs, expectations, 
and utilization in the design of our web-based survey. In 
the present study, we focus on these specific questions.
Although similar healthcare aspects have already been 
investigated in an international survey of a mixed patient 
population living with more common causes of spastic-
ity (e.g. stroke, multiple sclerosis, traumatic brain injury) 
[8], these issues have not yet been investigated in patients 
with inherited and progressive forms of spastic parapa-
resis. Furthermore, the experienced treatment effects 
reported in the abovementioned international survey 
were solely focused on botulinum toxin injections, not on 
pharmacological treatment in general.
Hence, in the present study, we report the data from 
our web-based survey addressing the healthcare needs, 
expectations, utilization, and experienced treatment 
effects amongst patients with pure HSP in the Nether-
lands [5]. The specific research questions were: (1) What 
needs do patients report regarding the symptoms and 
consequences of spastic paraparesis? (2) What treat-
ment effects do patients expect at forehand? (3) Which 
healthcare professionals do they consult and how often? 
(4) Which interventions are proposed by their health-
care providers? and (5) What pharmacological treatment 
effects do they experience?
Methods
Study design and setting
An online survey was conducted between January 2017 
and June 2017 in the Netherlands amongst community 
dwelling persons with HSP. The content of the survey 
aimed to identify the experienced consequences of liv-
ing with inherited and progressive spastic paraparesis, as 
well as the experienced needs and expectations regard-
ing clinical management. As the data on the experienced 
consequences have been reported in our previous pub-
lication [5], the current study focused on the healthcare 
needs, expectations, utilization and experienced effects 
regarding clinical management. The study was approved 
by the regional medical ethics committee “Commissie 
Mensgebonden Onderzoek Arnhem-Nijmegen” (num-
ber: 2016-2922), and conducted according to the declara-
tion of Helsinki.
Participants
Participants were recruited in three different ways. First, 
on our request, the national patient organization for neu-
romuscular disorders in the Netherlands (‘Spierziekten 
Nederland’; www. spierziekten.nl) invited their mem-
bers of the HSP working group by sending an email with 
information about the web-based survey. Second, all 
patients with pure HSP known at the expert center for 
rare and genetic movement disorders of the Radboud 
University Medical Center in Nijmegen were sent a let-
ter with information about the survey. Third, all people to 
whom we reached out by either of the above-mentioned 
ways were asked to share their invitation with relatives 
suffering from HSP. All invited persons and relatives 
could then apply to participate by sending an email to 
one of the researchers (BvL). After receiving an email in 
which the person stated to be willing to participate, BvL 
sent a unique link to the web-based questionnaire to each 
for a substantial proportion of the HSP population, also involving professionals with a primary occupational and/or 
psychosocial orientation.
Keywords: Hereditary spastic paraplegia, Spasticity, Survey, Patient-reported outcomes, Needs assessment, 
Healthcare utilization, Experienced treatment effects
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potential participant. People were eligible if they were 
18 years or older and had genetically confirmed HSP or, 
according to the recruiting researcher (BvL) and the sen-
ior author (AG), were very likely to have HSP based on 
their clinical symptoms and family history.
Data collection
The structure and content of the survey were designed by 
a team of expert physicians, physical therapists, research-
ers, and persons with HSP, as described in our previous 
publication [5]. Part of the questionnaire (category D) 
was based on a previous international survey amongst 
patients living with spasticity [8]. This was extended 
with questions based on the findings from a qualitative 
study amongst patients living with pure HSP, who were 
interviewed about the daily life consequences of spastic 
paraparesis and related healthcare needs [6]. In addi-
tion, representatives of the national patient organization 
were consulted. The survey was sent to the participants 
using Castor electronical data capture (Castor EDC 
v2020.1.15).
The content of the survey was categorized in four cat-
egories: A. participant characteristics, B. complaints 
and activity limitations, C. loss of motor capacities, 
and D. healthcare needs and interventions. For the cur-
rent study, only the categories A and D were used. The 
posed questions and the accompanying answering cat-
egories are listed in the additional file 1. To some extent, 
the amount of questions was variable for each partici-
pant, depending on their answer to a preceding question. 
Answering options were based on multiple choice, but 
some questions included a free entry format as one of the 
options. Completion of all questions took about 20 min, 
but there was no set time limit. Participants were allowed 
to pause during the questionnaire and continue at a later 
moment in time.
To ensure the inclusion of a homogeneous sample of 
persons with pure HSP, specific questions were included 
to identify patients with a complicated form of HSP and/
or with neurological comorbidity.
Data analysis
We excluded persons who confirmed that they had a 
complicated form of HSP (i.e. a genetic defect invariably 
associated with a complicated form of HSP and/or upper 
limb paresis, speech problems, cognitive disorders); or 
stated to have any neurological comorbidity that might 
interfere with spasticity, motor control, or physical fit-
ness and activity. Furthermore, we excluded persons who 
reported that they suffered from spasticity for less than 
one year because of their limited experience with clinical 
management.
Data was exported from Castor into Excel files, which 
were imported into a statistical software program. 
Descriptive statistics were run in SPSS (IBM Corp. 
Released 2017, IBM SPSS Statistics for Windows, Version 
25.0. Armonk, NY: IBM Corp).
Results
A total of 194 invitations were sent to persons who were 
interested in participation, of whom 166 (86%) fully com-
pleted the questionnaire. After excluding 57 respondents 
based on the predefined exclusion criteria, a total of 109 
(66%) questionnaires were used for analysis. Participant 
characteristics are displayed in Table 1. The mean age of 
the respondents was 52.8 years (SD 14.2). Fifty-seven per-
sons (52%) had a known genetic defect, with SPG4 being 
the most frequently reported subtype (36/57 = 63%). 
Almost 50% of the participants had a disease duration 
of more than 15  years and more than 50% were unem-
ployed, retired, or had a formally identified occupational 
incapacity. Almost 50% of the respondents reported 
micturation problems and used walking aids outdoors, 
whereas merely 12% was able to walk 100–1000  m out-
doors without walking aids. The degree of motor disabil-
ity and autonomic dysfunction (e.g. bladder dysfunction) 
have been reported in detail in our previous publication 
[5].
Needs
Participants were asked to indicate the amount of atten-
tion (answering options: none, some, a lot) required 
during consultation with their physician for the health-
care needs regarding the experienced impairments and 
disabilities (see Fig.  1). The majority of the participants 
(80%) prioritized gait impairments, followed by muscle 
stiffness (72%) and impaired balance (65%), all requiring 
“a lot of attention” (answering options see Fig. 1). Other 
relevant topics were: pain, muscle weakness, muscle 
cramps, physical and mental fatigue, fear of falling, emo-
tional problems, impaired self-care capacity, impaired 
sleep, and problems with employment and hobbies; all 
requiring minimally “some attention” in at least 60% of 
the participants.
Expectations
The majority of the participants (63%) expected ben-
eficial effects of the proposed interventions on gait (see 
Table  2). Other expectations, such as improved self-
confidence, well-being, self-care, night rest, and reduc-
tion of pain and spasticity were less prevalent (< 33%), 
as were expectations related to enjoying leisure time and 
hobbies, returning to previous routines, employment, 
perform simple tasks, or drive a car. In the free entry 
fields, four participants stated that they did not have any 
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expectations of the proposed interventions, whereas two 
participants had the expectation that treatment would 
slow down the progression of their disease.
Healthcare professionals
Eighty-two percent of the participants had no or less than 
one consultation per year with a neurologist, whereas 
16% visited a neurologist once or twice a year. The 
remaining 2% had three or more neurological consulta-
tions per year. As for consultations with a rehabilitation 
physician, 53% of the respondents had no or less than one 
consultation per year, 31% visited a rehabilitation phy-
sician once or twice a year, and the remaining 16% had 
three or more consultations per year.
Thirty-four percent of the participants had no consul-
tations with a physiotherapist, 14% was treated by a phys-
iotherapist once or twice per month, and 52% was treated 
more than three times per month. As for occupational 
therapy, 95% of the participants did not receive any con-
sultations. Four percent visited an occupational therapist 
once or twice per month and 1% percent had more than 
three visits per month.
In everyday life, 49% of the participants did not need 
help from others, whereas others relied on the support 
from relatives (37%) or professional caregivers (12%). 
Two percent of the participants did not know how to 
organize support for the challenges they experienced in 
everyday life.
Proposed interventions
Participants reported that a wide range of pharmaco-
logical and non-pharmacological interventions were pro-
posed by their treating physicians (see Table 3).
Non‑pharmacological interventions
Physiotherapy was by far the most often proposed non-
pharmacological intervention (81%), followed by ortho-
pedic footwear (55%) and splints (28%). Sometimes 
coaching and support (e.g. psychological support and 
stress reduction), education, occupational therapy, social 
work, and fatigue management programs were proposed. 
Orthopedic surgery was proposed to only a small num-
ber of participants.
Pharmacological interventions
Oral spasmolytic drugs (41%) were most often proposed, 
followed by intramuscular botulinum toxin (BTX) injec-
tions (26%). To a small number of participants (5%), the 
possibility of intrathecal baclofen administration (ITB) 
was proposed. A combination of pharmacological inter-
ventions was advised to 14% of the participants, whereas 
38% reported to have not been offered any spasmolytic 
treatment.
Pharmacological interventions were mainly focused on 
reducing muscle stiffness, muscle cramps, and improving 
balance and gait. If pharmacological interventions were 
proposed, 72% of the participants were informed by their 
physician about possible side-effects. Insufficient infor-
mation about the pros and cons of oral medication was 
reported by 27%. For BTX injections and ITB these num-
bers were 8% and 20%, respectively.
Table 1 Participant characteristics (N = 109)
Characteristics n
Sex (men/women) 54/55
Age in years (Mean (SD)) 52.8 (14.2)










Affected first-degree relatives 83
Duration of spasticity symptoms (years)
 1–5 years 21
 5–10 years 21
 10–15 years 16
 More than 15 years 51
Micturation problems 49
Use of electrical wheelchair outdoors 29
Use of walking aids outdoors 50







 Joint disorders 13
 Cardiac problems 4
 Other 7
Employment
 Full-time work 27





 Occupational incapacity 27
  Fully disabled (100%) 21
  Mostly disabled (66–99%) 6
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Before receiving an intervention, 43% of the partici-
pants was subjected to an instrumented clinical gait anal-
ysis (including 3-D motion capture for kinematics, force 
plates for kinetics, and surface electromyography for 
muscle activation patterns). To those who were proposed 
orthopedic surgery, instrumented 3-D gait analysis was 
performed in 69% of the cases.
Experienced pharmacological treatment effects
Figure 2 provides an overview of the percentage of par-
ticipants that experienced specific treatment effects 
of pharmacological interventions. Independent of the 
type of intervention, 35–46% of the participants experi-
enced decreased spasticity and improved general physi-
cal fitness. Other experienced effects differed per type of 
pharmacological intervention. Improved gait and move-
ment was more likely to occur after treatment with BTX 
injections (35–38%), compared to oral drugs (7–13%) or 
ITB (20–25%), whereas pain reduction and easier self-
care and self-rehabilitation were most likely after ITB 
(20–40%). The experienced effects on falls reduction 
were best for BTX injections and ITB (20–21%). Sleep-
ing responded best to oral drugs and ITB (16–20%). A 
substantial proportion of the participants experienced no 
effects at all from oral drugs (29%), BTX injections (29%), 
or ITB (40%).
Treatment with oral spasmolytic drugs was discontin-
ued in 13% of the participants, mainly because of fatigue. 
Fig. 1 Participants’ needs in terms of required attention during consultation for their experienced problems (N = 109)
Table 2 Expected effects of proposed interventions (N = 109)





Enjoying leisure time and hobbies 26
Improved self-care 22
Returning to previous routines 20
Absence of pain 19
Improved night rest 15
Absence of spasticity 15
Being able to work 13
Better performance of simple tasks 12
Driving a car 9
Page 6 of 10Kerstens et al. Orphanet J Rare Dis          (2021) 16:283 
Treatment with BTX injections was ceased in 7% of the 
participants, due to absence of effect. ITB was ceased in 
one of the 5 participants, because of too much muscle 
weakness.
The effect of the pharmacological treatment was mainly 
evaluated during the subsequent consultation with the 
treating physician. Thirty-five percent of the participants 
reported that they were not asked for feedback regard-
ing the effects of the intervention. Figure  3 shows the 
frequency of the methods used for providing feedback 
about the effects of the pharmacological interventions.
Discussion
This survey investigated the healthcare needs, expecta-
tions, and utilization regarding spasticity management 
in a sample of 109 persons suffering from pure HSP in 
the Netherlands. We found that needs and expectations 
were primarily focused on relief of muscle stiffness and 
reduction of balance and gait impairments. Yet, many 
participants also expressed a need for relief of pain, mus-
cle cramps, fatigue, and fear of falling as well as reduction 
of emotional problems, self-care and sleeping problems, 
and problems with employment and hobbies. Notably, 
participants’ expectations regarding the latter domains 
were less prevalent than their needs. As for the health-
care providers involved, rehabilitation physicians were 
consulted more often than neurologists, and physi-
otherapists much more than occupational therapists. 
Physiotherapy, orthopedic footwear, and splints were the 
most often proposed non-pharmacological interventions, 
whereas oral spasmolytic drugs were the most often 
administered pharmacological intervention, followed by 
intramuscular BTX injections. While both types of phar-
macological intervention were experienced by partici-
pants to reduce spasticity and improve general physical 
fitness, improved motor control was deemed more likely 
Table 3 Interventions proposed by treating physicians (N = 109)




 Orthopedic footwear 55
 Splints 28
 Postural exercises 15
 Massage 15
 Psychological support 12
 No intervention 10
 Ankle–foot surgery 9
 Hip surgery 4
 Stress reduction 2
 Education 2
 Occupational therapy 2
 Knee surgery 2
 Social work 1
 Osteopathy 1
 Fatigue management 1
 Lower spine surgery 1
Pharmacological interventions
 Oral spasmolytic drugs 41
 Intramuscular botulinum toxin injections 26
 Intrathecal baclofen 5
Fig. 2 Experienced effects of oral spasmolytics (N = 45), botulinum toxin injections (N = 28), and intrathecal baclofen (N = 5)
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after focal BTX treatment, whereas pain reduction and 
improved night rest were more likely to occur after sys-
temic treatment (intrathecally more than orally).
Healthcare needs and expectations
The participants’ needs as observed in this survey are in 
line with the results of our qualitative study amongst 14 
persons with pure HSP [6]. In the current study, we were 
able to quantify these needs, showing that 65–80% of the 
participants asked for a primary focus on relief of lower-
limb muscle stiffness and reduction of balance and gait 
impairments. Nevertheless, many participants (> 60%) 
also expressed the need for substantial clinical attention 
being directed at relief of pain, muscle cramps, fatigue, 
and fear of falling as well as a focus on improving soci-
etal participation and emotional well-being. Surprisingly, 
despite the fact that 49% of the respondents reported 
micturation problems (see Table  1), only 3% expressed 
the need of solving these problems. This apparent con-
tradiction may be caused by the absence of a predefined 
answering option in the questionnaire. Therefore, in-
depth exploration of individual patient needs—in con-
junction with caregivers—may help to disclose needs in 
people with HSP that may otherwise remain unnoticed. 
In addition, because physicians and physiotherapists typ-
ically tend to pay more attention to sensorimotor symp-
toms than emotional and participation problems, our 
findings make a plea for a more interdisciplinary biopsy-
chosocial approach to the clinical management of people 
with HSP, also involving professionals with a primary 
occupational and/or psychosocial orientation.
Remarkably, not many participants expressed expec-
tations in the domains of non-motor symptom relief, 
self-care, returning to previous daily-life activities, or 
employment. This finding may be related to the fact 
that HSP is a progressive inherited disease [2] that 
forces patients to constantly adapt to slow increments 
in physical impairments and activity limitations. In this 
perspective, people with HSP are hoping to slow down 
physical deterioration rather than expecting improve-
ment. This notion is supported by the finding that only 
15% of our participants expected to ever be free of spas-
ticity, while no more than 20% expected to be able to 
return to previous routines after treatment. These find-
ings are in contrast to the results of an international 
survey amongst persons with various causes of acquired 
spasticity, such as stroke, multiple sclerosis and traumatic 
brain injury, of whom two thirds expected to achieve 
absence of spasticity [8]. This latter study also found a 
larger proportion of patients being treated with pharma-
cological interventions (73% BTX injections and 57% oral 
spasmolytic drugs) as well as more patients experiencing 
treatment effects (81% less muscle stiffness and 9% no 
effect). Apparently, there is a difference in expectations, 
proposed interventions, and experienced effects between 
persons with inherited progressive spasticity versus those 
with acquired chronic spasticity. Apart from the progres-
siveness of their spasticity, people with pure HSP have 
often witnessed relatives coping with progressive spastic 
paraparesis. Instead, people with acquired chronic spas-
ticity, e.g. due to stroke, may have experienced regres-
sion of paresis and/or spasticity after disease onset. It is 
also possible that healthcare providers are more hopeful 
and willing to intervene in patients with acquired, non-
progressive spasticity compared to those with inherited, 
progressive spasticity. Based on the current results and 
our clinical experience, we assume that the majority of 
people with pure HSP have rather realistic expectations 
with regard to effects of spasticity management, but are 
underinformed with regard to the possibilities of other 
forms of clinical management (e.g. occupational therapy, 
energy conservation management, psychosocial inter-
ventions, vocational advice). Our previous qualitative 
study has shown that—in this perspective—persons with 
HSP ask for adequate information and coaching by their 
healthcare providers [6]. Healthcare professionals should 
incorporate this knowledge in their treatment approach.
Healthcare utilization and experienced treatment effects
Rehabilitation physicians tended to be consulted more 
frequently than neurologists by our participants. This 
observation is probably characteristic of the Dutch 
healthcare system. In the Netherlands, the diagnostic 
phase of HSP is typically led by neurologists, whereas 
spasticity management largely takes place within reha-
bilitation teams supervised by rehabilitation physi-
cians. More interestingly, only a few participants had 
consulted an occupational therapist, despite the fact 
that limitations in activities and participation were fre-
quently reported. This is remarkable given the fact that 
Fig. 3 Methods of providing feedback on treatment effect
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occupational therapy is easily accessible in rehabilitation 
centers, hospitals and community practices all over the 
Netherlands. In addition, costs of occupational therapy 
are reimbursed by all Dutch health insurances. Probably, 
there is unawareness amongst people with HSP as well as 
amongst their treating clinicians of the services and solu-
tions that occupational therapists can provide. A similar 
explanation may underlie the low rate of consultation by 
professionals with psychosocial expertise. In neurologi-
cal conditions such as Parkinson or stroke, occupational 
therapy has proven to be effective [9, 10]. In their quali-
tative study in 2013, Grose et al. concluded that persons 
healthcare professionals should be more aware of the 
emotional aspects of living with HSP [11].We believe that 
our data justify more involvement of both occupational 
therapists and psychosocially oriented disciplines in the 
clinical management of people with HSP.
Of all interventions, physiotherapy was most often 
provided, but our data do not allow any conclusions 
regarding the content or experienced effects of physi-
otherapy. More than half of the participants used ortho-
pedic footwear, which may be related to a higher risk of 
ankle–foot deformities and ankle instability associated 
with HSP [12]. Splints were used by more than a quarter 
of all patients, probably to support lack of foot elevation 
and to prevent tripping. Despite limited evidence in the 
literature [13] and a frequent lack of effects experienced 
by almost one third of the users in the current study, oral 
spasmolytic drugs were used by 41% of our participants. 
In contrast, an almost equal number of participants (38%) 
had never been offered any spasmolytic treatment. Of 
those who did use oral medication, almost one third felt 
underinformed. These results seem to point towards a 
pharmacological area characterized by a variable level of 
quality of evidence, and sometimes contradicting guide-
lines and recommended monitoring tools [14]. The fig-
ures on informed consent with BTX and ITB treatment 
seem to be slightly better, but inferences regarding their 
experienced effect compared to oral spasmolytic drugs 
cannot be made due to selection bias and the (very) small 
numbers of people on these more invasive treatments. 
Considering the type of treatment effect, especially par-
ticipants with an ITB pump seemed to have a greater 
likelihood of experiencing pain reduction, easier self-care 
and self-rehabilitation, and better sleep, whereas those 
who received BTX treatment seemed to have a higher 
chance of attaining improved motor control and capacity. 
But also in this respect, our results should be interpreted 
with caution.
Both the natural daily fluctuations in spasticity and 
the fluctuations induced by interventions such as botu-
linum toxin require careful communication between 
patients and healthcare providers to determine the 
optimal timing of (subsequent) interventions. Remark-
ably, more than one third of our respondents was not 
asked for any feedback on treatment results, whereas 
41% was asked for feedback during subsequent con-
sultations. To support patients in providing feedback, 
systematic monitoring of patient-relevant outcomes is 
crucial. It will help to tailor interventions to individual 
needs, to evaluate the effect of interventions, and to 
optimize timing [15].
Strengths and limitations
A strength of this study is that we analyzed question-
naires from a relatively large group of people with pure 
HSP in the Netherlands, given the relatively low esti-
mated prevalence of 800 persons with pure HSP in our 
country [16]. Our study sample also showed an equal 
sex distribution, a wide age range, and a large variation 
in duration of spasticity and underlying genetic defects, 
which underscores its representativeness for the Dutch 
population with pure HSP. As we included only partici-
pants with pure HSP, our findings cannot be general-
ized to people with more complicated forms of HSP. 
Another limitation is that our results cannot readily 
be generalized to people with HSP in other countries, 
given the differences in healthcare systems. However, 
since our results are in line with the findings of Grose 
et al., who studied the experiences of persons with HSP 
and healthcare professionals in England [11], we believe 
that a cautious use of our findings in the realm of West-
ern European countries is warranted.
Another limitation is that only subjects without 
a positive family history or genetic diagnosis were 
checked for a formal diagnosis of pure HSP made by a 
neurologist. By including and excluding subjects based 
on specific questions, we tried to obtain a homogene-
ous sample with pure HSP, but it is possible that some 
people were incorrectly enrolled or excluded.
Our web-based survey was partly (category D) based 
on a previous international survey and extended with 
questions based on findings of a previous qualita-
tive study [6] and input from representatives from the 
national patient organization. Yet, the involvement 
of healthcare professionals, who might have precon-
ceptions regarding important aspects of HSP, might 
have biased its content. Furthermore, some questions 
allowed only dichotomous answers (yes /no), which 
might have influenced the relatively low scores for 
expectations regarding symptom relief (as participants 
could not indicate an expected partial relief ). The fact 
that answers were given in complete anonymity and 
without any time limit are considered strengths.
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Conclusion
Based on this web-based survey in the Netherlands, 
there seems to be ample room for improvement to 
meet and attune the healthcare needs and expectations 
of people with pure HSP. Besides relief of their motor 
symptoms and incapacities, they express a clear need 
to address non-motor symptoms and functional limi-
tations, for instance regarding pain, fatigue, emotional 
problems (i.e., lack of self-confidence, fear of falling), 
impaired sleep and self-care, and problems with occu-
pation and participation. In addition, the provision of 
adequate information about pharmacological interven-
tions seems to be insufficient for many patients to allow 
shared decision making. These conclusions warrant a 
more pro-active attitude of healthcare providers as well 
as a interdisciplinary approach for a substantial propor-
tion of the HSP population, also involving professionals 
with a primary occupational and/or psychosocial ori-
entation. Regarding content of spasticity management 
in this population, there is a need for (inter)national 
guidelines, given the variety of clinical practice and the 
sparsity of clinical evidence. Hence, we recommend 
that future research aims at both improving spasticity 
management and broadening the scope of clinical man-
agement in people with pure HSP.
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